Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1364Prostatic Neoplasms 1106Multiple Myeloma 873Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

ropinirole 1pasireotide 1Lapatinib 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Prolactinoma × Clear all
NCT03038308 2024-06-04

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Columbia University

Phase 1/2 Completed
16 enrolled 8 charts

Hyperprolactinemia, Prolactinoma

NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Cedars-Sinai Medical Center

Phase 2 Completed
9 enrolled 11 charts
Endocrine

Pituitary Neoplasms, Prolactinoma

NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Universidade Federal do Rio de Janeiro

Phase 2/3 Completed
21 enrolled 4 charts

Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡